Dementia: are younger generations really less likely to develop the disorder, as a recent study has claimed?
Dementia affects over 57 million people worldwide – and this number is only projected to grow. By 2030, 78 million people are estimated to have dementia. By 2050, it's projected that number will reach 139 million people.
Despite this, a surprising new study has suggested that dementia risk has actually declined with each generation. However, there are good reasons to be sceptical of this finding.
The researchers analysed data from 62,437 people aged 70 and over. Data was collected from three longitudinal cohort studies on ageing, including one conducted in the US, one in Europe and one from England.
To conduct their analysis, the researchers compared probable dementia diagnoses from people born in eight different generation cohorts. The people in the first cohort were born in 1890-1913, while those in the most recent cohort were born in 1944-48.
Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences.
The researchers employed an algorithm that suggested probable dementia diagnosis. This was based on participants' demographic characteristics, as well as their cognitive performance and everyday functioning skills (including how well they were able to perform daily functions, such as washing and feeding, and how well they could remember things). These are standard assessment tools used in clinical practice to diagnose dementia.
To then validate the algorithm's projections on probable dementia cases, the predictions were compared against a sub-sample of participants from the US Aging, Demographics and Memory study who had a clinical diagnosis of dementia.
The participants in this study had undergone a rigorous three- to four-hour cognitive assessment. The algorithm used to create dementia projections showed an over 85% agreement with clinical diagnosis data from that sub-sample data.
Once dementia status was calculated, the authors computed two models to ascertain the relationship between age, cohort and dementia onset. They also included gross domestic product (GDP) in their analyses, as there's a correlation between GDP and health – with research showing that people in higher-income nations tend to be healthier than those living in lower-income nations.
Their findings revealed that dementia cases decreased for each subsequent generation. For instance, in the US, the algorithm indicated that 25% of people born between 1890-1912 developed dementia, while only 15% of those born in the most recent cohort (1939-1943) developed dementia.
In England, almost 16% of people born between 1924-28 were indicated to have developed dementia, compared with around 15% in those born between 1934-38. This effect was also apparently more pronounced for women than for men.
It remains unclear why dementia cases fell across the generations, with more recent cohorts having reduced dementia cases.
What does this mean? And how does this compare against existing projections?
While the authors used a large sample from three established ageing research cohorts, the findings are based on data from high-income countries only.
It's well known that dementia can be better diagnosed and cared for in high-income countries, where there are more and better healthcare services and professionals. Dementia is hugely stigmatised in low- and middle-income countries as well. As a result, many people are not as aware of dementia as people living in high-income societies.
This means people in lower-income countries may know less about the associated risk factors for dementia and are less likely to receive a diagnosis and support. This is particularly relevant given the fact that most people with dementia reside in low- and middle-income countries.
With a lack of cohort data on older adults and dementia cases in low- and middle-income countries, the findings from this study do not provide representative projections on dementia diagnoses globally.
It's also important to consider the methods the authors used in their study. The authors used a prediction model. Although this model had high agreement with clinical diagnosis, there are still cases of dementia that will have been missed out as a result.
Similarly, the authors did not distinguish between dementia subtypes in their modelling. Dementia is just an umbrella term. About 60-70% of dementia cases are actually Alzheimer's disease.
But there are also many rarer subtypes – such as Lewy Body dementia or semantic dementia. Each subtype brings with it different symptoms. A generic model is unlikely to pick up each subtype dementia case correctly.
All these factors may possibly explain how the study came to their conclusions.
Dementia cases worldwide are actually predicted to increase. As such, the findings from this study should be considered with caution. It may not be the case that dementia prevalence continues to fall for more recently born generations.
Part of the reason for these projections is due to the fact that people are living longer and growing older. Dementia primarily affects people aged over 65, so with more people living to be over 65 this means that more people will be at risk of developing the disorder.
The world population is growing, too. So naturally we're going to see more people living with dementia – particularly in low- and middle-income countries, where people may have less knowledge of dementia symptoms and may be less able to address the modifiable risk factors linked to greater risk, due to poor healthcare infrastructure.
We know that overall, people from more socioeconomically disadvantaged backgrounds experience greater health inequalities – and these health inequalities may contribute to increased risk of dementia. But as this factor was not taken into account in the study, it's difficult to know whether there really will be any differences in the projected number of dementia cases in younger generations.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Clarissa Giebel receives funding from the ESRC and the NIHR. She sits on the Scientific Advisory Committee of the Lewy Body Society.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 hours ago
- Yahoo
Dementia: are younger generations really less likely to develop the disorder, as a recent study has claimed?
Dementia affects over 57 million people worldwide – and this number is only projected to grow. By 2030, 78 million people are estimated to have dementia. By 2050, it's projected that number will reach 139 million people. Despite this, a surprising new study has suggested that dementia risk has actually declined with each generation. However, there are good reasons to be sceptical of this finding. The researchers analysed data from 62,437 people aged 70 and over. Data was collected from three longitudinal cohort studies on ageing, including one conducted in the US, one in Europe and one from England. To conduct their analysis, the researchers compared probable dementia diagnoses from people born in eight different generation cohorts. The people in the first cohort were born in 1890-1913, while those in the most recent cohort were born in 1944-48. Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences. The researchers employed an algorithm that suggested probable dementia diagnosis. This was based on participants' demographic characteristics, as well as their cognitive performance and everyday functioning skills (including how well they were able to perform daily functions, such as washing and feeding, and how well they could remember things). These are standard assessment tools used in clinical practice to diagnose dementia. To then validate the algorithm's projections on probable dementia cases, the predictions were compared against a sub-sample of participants from the US Aging, Demographics and Memory study who had a clinical diagnosis of dementia. The participants in this study had undergone a rigorous three- to four-hour cognitive assessment. The algorithm used to create dementia projections showed an over 85% agreement with clinical diagnosis data from that sub-sample data. Once dementia status was calculated, the authors computed two models to ascertain the relationship between age, cohort and dementia onset. They also included gross domestic product (GDP) in their analyses, as there's a correlation between GDP and health – with research showing that people in higher-income nations tend to be healthier than those living in lower-income nations. Their findings revealed that dementia cases decreased for each subsequent generation. For instance, in the US, the algorithm indicated that 25% of people born between 1890-1912 developed dementia, while only 15% of those born in the most recent cohort (1939-1943) developed dementia. In England, almost 16% of people born between 1924-28 were indicated to have developed dementia, compared with around 15% in those born between 1934-38. This effect was also apparently more pronounced for women than for men. It remains unclear why dementia cases fell across the generations, with more recent cohorts having reduced dementia cases. What does this mean? And how does this compare against existing projections? While the authors used a large sample from three established ageing research cohorts, the findings are based on data from high-income countries only. It's well known that dementia can be better diagnosed and cared for in high-income countries, where there are more and better healthcare services and professionals. Dementia is hugely stigmatised in low- and middle-income countries as well. As a result, many people are not as aware of dementia as people living in high-income societies. This means people in lower-income countries may know less about the associated risk factors for dementia and are less likely to receive a diagnosis and support. This is particularly relevant given the fact that most people with dementia reside in low- and middle-income countries. With a lack of cohort data on older adults and dementia cases in low- and middle-income countries, the findings from this study do not provide representative projections on dementia diagnoses globally. It's also important to consider the methods the authors used in their study. The authors used a prediction model. Although this model had high agreement with clinical diagnosis, there are still cases of dementia that will have been missed out as a result. Similarly, the authors did not distinguish between dementia subtypes in their modelling. Dementia is just an umbrella term. About 60-70% of dementia cases are actually Alzheimer's disease. But there are also many rarer subtypes – such as Lewy Body dementia or semantic dementia. Each subtype brings with it different symptoms. A generic model is unlikely to pick up each subtype dementia case correctly. All these factors may possibly explain how the study came to their conclusions. Dementia cases worldwide are actually predicted to increase. As such, the findings from this study should be considered with caution. It may not be the case that dementia prevalence continues to fall for more recently born generations. Part of the reason for these projections is due to the fact that people are living longer and growing older. Dementia primarily affects people aged over 65, so with more people living to be over 65 this means that more people will be at risk of developing the disorder. The world population is growing, too. So naturally we're going to see more people living with dementia – particularly in low- and middle-income countries, where people may have less knowledge of dementia symptoms and may be less able to address the modifiable risk factors linked to greater risk, due to poor healthcare infrastructure. We know that overall, people from more socioeconomically disadvantaged backgrounds experience greater health inequalities – and these health inequalities may contribute to increased risk of dementia. But as this factor was not taken into account in the study, it's difficult to know whether there really will be any differences in the projected number of dementia cases in younger generations. This article is republished from The Conversation under a Creative Commons license. Read the original article. Clarissa Giebel receives funding from the ESRC and the NIHR. She sits on the Scientific Advisory Committee of the Lewy Body Society.
Yahoo
20 hours ago
- Yahoo
USAging Announces New Public Awareness Campaign to Raise Visibility of Area Agencies on Aging
Washington, DC, June 24, 2025 (GLOBE NEWSWIRE) -- USAging is celebrating 50 years as the national organization that represents Area Agencies on Aging (AAAs) and Title VI Native American Aging Programs. As part of the 50th anniversary, USAging has launched a new public awareness campaign—Area Agencies on Aging: Helping You Live Long and Stay Strong. The goal of this campaign is to make the public aware of AAAs as a vital community resource and to educate consumers about the range of important services that AAAs offer to older adults, people with disabilities and caregivers. There are more than 600 AAAs serving every community across the country ready to help them to age well where most want—at home and in their community. All people hope to enjoy a long and healthy life—but many find that they need a little help as they go through the aging journey. 'Research has shown that two-thirds of older adults will need some support to age well at home,' said USAging CEO Sandy Markwood. 'But people often don't know about AAA services or seek them out until they are in crisis—thereby missing the opportunity to connect to the range of services that are available to help them age well.' Services Provided by AAAsFor Older Adults: Home-delivered and congregate meals: Nutritious meals at home or in group settings. In-home support: Assistance with daily tasks like bathing, cleaning and dressing. Transportation: Rides to medical appointments, stores and community activities. Health and wellness programs: Fall prevention, chronic disease management fitness classes. Benefits counseling: Help understanding and enrolling in Medicare, Medicaid and more. For Caregivers: Respite care: Short-term relief to prevent burnout. Training and support: Educational tools and support groups for caregivers. Information and referral: Guidance to local programs, services and community resources. 'By 2035, older adults are expected to outnumber children under age 18 for the first time in the history of this country,' said Markwood. 'By 2040, a full 22 percent of the American population will be 65 years or older. Currently, there are more than 53 million unpaid family caregivers in the United States. There has never been a more crucial time for people to learn about AAAs and the services that are available to them to help them live long and stay strong.'For more information, visit or connect with your local AAA by contacting the Eldercare Locator at 1-800-677-1116 or CONTACT: Bethany Coulter USAging 202.872.0888 bcoulter@ in to access your portfolio
Yahoo
2 days ago
- Yahoo
Mounjaro becomes available on the NHS: what to know and what to do if you're not eligible
Obesity remains one of the most pressing, and preventable, health challenges of our time. The UK is one of a number of countries undoubtedly struggling with it. It affects nearly every organ system in the body, contributing to cardiovascular conditions like coronary heart disease; musculoskeletal issues such as osteoarthritis and gout; and even the development of certain cancers, including of the breast, uterus and colon. Its impact on mental health is also significant. A few years ago, injectable weight-loss drugs entered clinical use and quickly captured public attention for their ability to promote rapid fat loss. Ozempic is available on the NHS, but only for managing type 2 diabetes. Wegovy is authorised for weight loss and cardiovascular risk reduction and is also available on the NHS, though access is currently limited to specialist weight management services. Now, a new option has emerged: Mounjaro, which is approved for both type 2 diabetes and weight loss. This dual-purpose drug is now available on the NHS, offering another potential tool in the fight against obesity. Demand is expected to be high. However, access will be limited at first, with strict eligibility criteria for NHS prescriptions. Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences. Mounjaro (tirzepatide) is a once weekly injectable medication designed to help control blood-sugar levels. It works by boosting the secretion and effects of insulin, improving glycaemic control in people with Type 2 diabetes. It also slows gastric emptying — the process by which food leaves the stomach — and enhances feelings of fullness by acting on the brain. This combined effect reduces appetite and helps support weight loss. Compared to similar medications like Ozempic and Wegovy (both brand names for semaglutide), clinical trials found Mounjaro more effective, with some participants losing up to 20% of their body weight over a 72-week period. Read more: The NHS has introduced specific criteria to prioritise patients most in need. First, patients need a BMI of 40 or more (classified as morbid obesity). People from certain ethnic backgrounds, such as South Asian communities, may be eligible at a lower BMI due to higher clinical risk of health conditions. Second, at least four obesity-related health conditions must be diagnosed, including type 2 diabetes, hypertension (high blood pressure), dyslipidaemia (abnormal cholesterol or triglyceride levels), cardiovascular disease and obstructive sleep apnoea. (Some of these conditions often occur together; for example, high blood pressure and cholesterol.) Patients are encouraged to check their BMI and confirm their diagnoses before contacting a GP. This helps ensure appointments are used effectively and discussions remain focused. While the current criteria are strict, there is optimism that eligibility will broaden in the coming years to include people with lower BMIs and fewer co-morbidities. The NHS continues to offer a comprehensive weight-loss programme, tiered according to BMI and previous attempts at weight loss. Don't underestimate the value of group-based programmes or community referrals – when a healthcare professional refers a patient to a community-based health service for further care or support – many of which can be accessed via your GP. These services, such as the NHS digital weight management programme, support both individuals and families and can be highly effective for sustainable fat loss. GPs may also refer patients to online courses and structured exercise programmes. Lifestyle interventions, including increased physical activity and healthier eating, remain cornerstones of obesity treatment and are critical for long-term success, even when medications are used. Read more: Higher tier interventions may be considered if lifestyle changes fail or if the patient has significant co-morbidities. This is where medications like Mounjaro, or private prescriptions, may become relevant – albeit that the cost of the latter may be a limiting factor for some. Other treatments include Orlistat, a medication that reduces fat absorption in the gut. This can be effective for some but often causes unpleasant side effects, such as oily stools and gastrointestinal upset Gastric banding or surgery may also result in significant, sustained weight loss, but they come with risks, can lead to surgical complications, and recovery can be demanding It's also important to recognise that drugs like Mounjaro aren't suitable for everyone. They can cause side effects significant enough for people to stop using them, and in some cases, they may not work at all. In this new era of faster, medication-assisted weight loss, we must remember that long-term change is about more than quick fixes. Sustainable success comes from consistent effort, willingness to change and methods that are both practical and lasting. Medications can help, sometimes dramatically, but they're not the only answer. A return to basics, with tailored support and realistic goals, remains as relevant as ever. So whether you qualify for Mounjaro, are trying lifestyle changes, or are exploring other options, remember this: the journey to better health is personal, gradual and worth it. This article is republished from The Conversation under a Creative Commons license. Read the original article. Dan Baumgardt does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.